Does this say anything? I'm not sure.
PROMETIC LIFE SCIENCES INC. OBTAINS AN ADDITIONAL PATENT FOR ITS CHEMICAL LIBRARY OF LIGANDS - Protects billions of synthetic compounds to be used in high value commercial applications
MONTREAL, Nov. 9 /PRNewswire/ - ProMetic Life Sciences Inc. (ProMetic;
Toronto TSE symbol PLI), announced today that it was awarded U.S. Patent N. 6,117,996 which further consolidates the proprietary position of its enabling platform technology.
The issued patent covers Mimetic Ligands(TM) which are synthetic organic entities that exhibit high affinity and selective interaction with proteins such as monoclonal antibodies. Mimetic Ligands(TM) are used in large-scale
drug purification, chemical genomics, proteomics, drug discovery and drug development applications.
The patent provides proprietary protection for a library of ligands constituting billions of synthetic compounds from which promising lead candidates are screened and developed into high value commercial applications.
Resulting from a successful programme of collaborative research with Novo Nordisk A/S, the patent was filed jointly by ProMetic and Novo Nordisk.
Collaboration agreements with Novo Nordisk provide exploitation rights to Novo Nordisk for a small number of specific applications whereas exploitation rights for all other applications are vested with ProMetic. "This patent further exemplifies the novelty of ProMetic's platform technology" stated Pierre Laurin, President and CEO of ProMetic. "The pioneering work that was originally done in collaboration with Novo Nordisk has since evolved into collaborations with over 20 multinationals and biotech companies", added Mr. Laurin.
Since the initial patent filing in September 1995, ProMetic has significantly expanded its libraries of compounds and filed additional patent applications to further its proprietary position in the field of combinatorial chemistry and drug discovery.
With its libraries of compounds and other complementary and proprietary technologies and as a supplier of a critical enabling technology, ProMetic is strategically positioned to capitalize on the growth of the biopharmaceutical industry driven by monoclonal antibodies, chemical genomics and proteomics.
ProMetic owns proprietary enabling technology essential for use in large-scale drug purification, chemical genomics, proteomics, drug discovery and drug development. This technology can significantly reduce costs, increase
yield and improve purity of existing and new bio-pharmaceutical products.
ProMetic accomplishes this through strategic partnerships and in-house therapeutic development. The headquarters of ProMetic Life Sciences Inc. are in Montreal and it has operations in Canada, The United States and the UK. Its
shares are traded on the Toronto Stock Exchange under the ticker symbol PLI.
Additional information is available on the company's website: prometic.com |
